• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytometry: The Journal of the Society for Analytical Cytology >Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using alpha-difluoromethylornithine.
【24h】

Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using alpha-difluoromethylornithine.

机译：核形态学作为使用α-二氟甲基鸟氨酸化学预防宫颈癌的中间终点生物标志物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The use of nuclear morphometry as an intermediate endpoint biomarker is described in a Phase I, dose-seeking trial of chemoprevention of cervical cancer, using the agent alpha-difluoromethylornithine (DFMO). Thirty patients with grade III cervical intraepithelial neoplasia (CIN III) were enrolled, and these received daily doses of DFMO at 0.06-1.0 mg/m(2) for a period of 1 month. Fifteen patients were observed to have a complete or partial regressive response to the agent, as assessed by histopathology. No significant differences in cell feature measurements were found between responders and nonresponders in specimens obtained before treatment, indicating that it may be difficult to predict response on the basis of these measurements. In specimens collected after treatment, large differences in morphometric features were observed between responders and nonresponders, indicating a differential effect of DFMO. Significantly modulated features were considered in terms of their correlations with CIN grade, which was determined from an independent set of measurements from archival tissue. Differences between features were consistent with a deletion of cells with high grade nuclei in the responders, and with the persistence of a more heterogeneous population of high grade cells in the nonresponders. Based on an independent set of measurements from archival material, a morphometric index of progression was derived, yielding a quantitative measure of the degree of nuclear atypia in these lesions. When applied to this trial, the morphometric index was seen to be specifically and consistently decreased in responsive lesions, and unchanged in nonresponders. The study indicates that morphometric features fulfill the requirements for an intermediate endpoint biomarker of cervical cancer chemoprevention. Copyright 1999 Wiley-Liss, Inc.
机译：在I期宫颈癌化学预防的剂量寻找试验中，使用试剂α-二氟甲基鸟氨酸（DFMO）描述了使用核形态学作为中间终点生物标志物。招募了30例III级宫颈上皮内瘤样病变（CIN III），这些患者每天接受0.06-1.0 mg / m（2）的DFMO剂量，为期1个月。通过组织病理学评估，观察到15名患者对该药剂具有完全或部分的退化反应。在处理前获得的标本中，反应者和非反应者之间在细胞特征测量方面未发现显着差异，这表明根据这些测量结果可能难以预测反应。在处理后收集的标本中，观察到反应者和非反应者之间的形态特征存在很大差异，这表明DFMO有不同的作用。根据其与CIN等级的相关性考虑了显着调节的特征，这是根据档案组织的一组独立测量确定的。特征之间的差异与应答者中具有高级核的细胞的缺失以及非应答者中高级细胞的更多异质群体的持续存在是一致的。基于来自档案材料的一组独立测量值，得出了进展的形态计量学指标，从而得出了这些病变中核非典型性程度的定量测量值。当应用于该试验时，形态学指标在反应性病变中被明确且持续降低，而在无反应者中则保持不变。研究表明形态特征满足宫颈癌化学预防中间终点生物标志物的要求。版权所有1999 Wiley-Liss，Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号